EverImmune

Recent Finacing

Equity

Recent Raise

$3.7M

EverImmune develops lyophilized, delayed‑release oral live biotherapeutic Oncobax AK (Akkermansia) and companion diagnostic to restore checkpoint inhibitor sensitivity in NSCLC and RCC, plus bacterial adjuvant pipeline.

Founded 2016

Ile-de-France, France

1-10

Private

everimmune.com

Highlights

Focus Areas

Biotechnology

Health Care

Recent Investors

Financials

$9.3M

Total Raised

2

Funding rounds

1

Investor

Team

Upgrade to view the team

See the team members at EverImmune.